News | April 11, 2021
NATCO receives approval for Ibrutinib tablets from ANDA
The approval is for Ibrutinib tablets 560 mg, 420 mg, 280 mg and 140 mg strengths
The approval is for Ibrutinib tablets 560 mg, 420 mg, 280 mg and 140 mg strengths
The government has taken all the effective measures to make healthcare affordable
This acquisition marks PPS’ foray into the development and manufacturing of peptide APIs
India produces 60% of the world’s vaccine
Report outlines the wide array of investment opportunities in various segments of India’s healthcare sector
Lupin will provide five lakh LupiSafe hand sanitizers to policemen and frontline workers deployed at strategic locations
Lonza Specialty Ingredients has become LifeClean’s first strategic industrial partner.
AdCOVID is a COVID-19 vaccine candidate that is administered via nasal spray.
The collaboration of two strong partners, CELLINK and UPM, builds confidence in making these treatments into an industrial and clinical standard, applied in a wider setting instead of remaining only within few hospitals.
NATCO's partner BPI plans to launch 2.5 mg, 5 mg and 7.5 mg strengths of the product shortly within the next few weeks.
Subscribe To Our Newsletter & Stay Updated
